AOD-9604: The "Fat-Burning Fragment" of Growth Hormone — Hype vs Evidence

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone, sold today as a "fat-burning peptide" on the strength of a story that is mostly true in mice and mostly false in people. In obese-mouse studies it stimulated fat breakdown without the growth effects of full growth hormone, which is genuinely interesting. The problem is the part marketing pages tend to skip: when AOD-9604 was actually tested in obese adults, it did not produce statistically significant weight loss versus placebo, and its developer terminated the obesity program in 2007.

If you have seen AOD-9604 promoted as a "lipolytic" or "fat-melting" peptide, or featured among the best peptides for longevity, this guide is the honest, high-level map of the whole compound, written to separate the hype from the evidence. We cover what it actually is, the famous mouse mechanism, why the human trials failed, what (if anything) it is still studied for, the doses people report, side effects, and its research-only legal status. The deep-dive spokes (full dosing math, the broader growth-hormone fragment family) point to dedicated guides so this page stays a clean hub.

Key Takeaways

• AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (the hGH 176-191 region, with a tyrosine added at the N-terminal end); the "AOD" stands for "anti-obesity drug" (Wikipedia, "AOD9604", retrieved 2026-06-15).
• It failed its key human weight-loss test. A 12-week trial showed only a modest 1.8 kg edge over placebo, and development was halted "following poor efficacy in a later 24 week trial" and terminated in 2007 (Wikipedia, "AOD9604", retrieved 2026-06-15).
• The "fat-burning" reputation rests on mouse data. In obese mice, the C-terminal hGH fragment increased fat oxidation and weight loss without competing for the growth-hormone receptor or inducing cell proliferation, but that result did not translate into meaningful human fat loss (Heffernan et al., International Journal of Obesity, 2001, retrieved 2026-06-15).
• It is not FDA-approved and is not a dietary ingredient. In December 2024, an FDA advisory committee reviewed AOD-9604 for the 503A compounding bulks list rather than approving it for sale (U.S. FDA, "December 4, 2024 PCAC Meeting", 2024, retrieved 2026-06-15).
• It is banned in sport. AOD-9604 "is still banned in athletes and tested for in competition," and was at the center of the Essendon AFL doping saga (Wikipedia, "AOD9604", retrieved 2026-06-15).
• Reported doses cluster around 250-500 mcg/day by subcutaneous injection, a community convention; the failed trials actually used a 1 mg oral tablet. These are reported figures, not validated dosing. The full ladder is a future dosing chart spoke.

What is AOD-9604?

AOD-9604 is a synthetic peptide made of 16 amino acids, copied from the tail end of the human growth hormone molecule, that was designed as a fat-loss drug. Its name is literally an abbreviation of "anti-obesity drug." It corresponds to the hGH 176-191 region (often sold as "HGH Fragment 176-191" with a small structural tweak), and it is studied and marketed almost entirely for one claimed purpose: burning fat.

Chemically, AOD-9604 is described as "an orally active, lipolytic 16-amino acid peptide fragment of human growth hormone" made of "HGH residues 176-191, with a tyrosine in place of the phenylalanine at the N-terminal end" (Wikipedia, "AOD9604", retrieved 2026-06-15). The added tyrosine is a stabilizing modification, which is the difference often cited between AOD-9604 and the plain "176-191" fragment. The idea behind the design was elegant: take only the part of growth hormone thought to drive fat metabolism, and leave behind the parts that raise IGF-1, affect blood sugar, or promote tissue growth. If injectable peptides are new to you, start with our how peptides work guide.

The single most important fact about AOD-9604 is the gap between that elegant idea and the actual human results. It was developed as a weight-loss drug, it was tested as a weight-loss drug, and it failed as a weight-loss drug. Everything else in this guide should be read through that lens.

Citation capsule. AOD-9604 ("anti-obesity drug 9604") is a synthetic, orally active, lipolytic 16-amino-acid peptide fragment of human growth hormone, corresponding to hGH residues 176-191 with a tyrosine substituted at the N-terminal end. It was developed as an anti-obesity candidate, is banned in sport, and is not approved by any regulator for human use. Source: Wikipedia, "AOD9604," 2026; CAS 221231-10-3; PubChem CID 71300630.

How is AOD-9604 supposed to work?

AOD-9604 is supposed to work by switching on fat breakdown (lipolysis) the way the tail end of growth hormone does, while skipping the hormone's growth and blood-sugar effects, so you could lose fat without the downsides of full growth hormone. That is the theory. The catch is that the supporting evidence is almost entirely from mice, and the effect did not carry over to humans.

In plain terms, researchers noticed that a specific tail region of growth hormone seemed responsible for its fat-burning action, so they built a stable fragment of just that region. In obese mice, the modified C-terminal fragment increased fat oxidation and reduced weight gain, and crucially it did so "without competing for the hGH receptor" and without inducing the cell proliferation that full growth hormone causes (Heffernan et al., International Journal of Obesity, 2001, retrieved 2026-06-15). That receptor-decoupling result, published by the Monash University group, is the entire scientific basis for the marketing claim that AOD-9604 "burns fat without affecting IGF-1 or insulin." It is an inference from animal data, not a proven human endpoint.

Here is what the proposed mechanism contributes, in simple terms:

• Stimulating lipolysis: the fragment is reported to push fat cells to release and burn stored fat, the action most associated with growth hormone's lean-tissue effects.
• Sparing the growth pathway: because it does not bind the growth-hormone receptor the way full hGH does, it is not expected to raise IGF-1 or drive tissue growth (shown in mice; not cleanly demonstrated in humans).
• Avoiding insulin resistance: full growth hormone can worsen insulin sensitivity, and the fragment was designed to avoid that liability.

The receptor-and-signaling deep dive (how the fragment is thought to act on fat cells, and how it relates to the wider growth-hormone-fragment family) is its own topic. We keep it at overview level here and link out to how peptides work for the foundations, since AOD-9604 is itself the GH-fragment (residues 176-191) that this section explains.

Our take: The mechanism story is the most seductive part of AOD-9604, because it is real, specific, and decades old. But "this works in obese mice" and "this works in obese humans" are two very different claims, and AOD-9604 is the textbook case of the first being true and the second not following.

Why did AOD-9604's weight-loss trials fail?

AOD-9604's human weight-loss trials failed because it did not produce statistically significant fat loss compared with placebo, so its developer halted the obesity program and terminated it in 2007. A short early trial hinted at a small effect, but the larger, longer trial that should have confirmed it did not.

This is the single most important and most often-omitted fact about AOD-9604. In a 12-week randomised trial, "subjects receiving AOD9604 lost, on average, 1.8 kg more than those receiving placebo" (Wikipedia, "AOD9604", retrieved 2026-06-15). That modest signal did not hold up: development "was halted following poor efficacy in a later 24 week trial," and "its development was terminated in 2007" (Wikipedia, "AOD9604", retrieved 2026-06-15). In other words, the compound was given a fair, multi-trial shot at proving it was an anti-obesity drug, and it did not clear the bar. The human weight-loss program spanned several studies and hundreds of participants before being abandoned, which makes "it just needs the right protocol" a hard argument to sustain.

What the mouse-to-human gap looks like

It helps to see the contrast directly. The fragment looked genuinely promising in rodents, where it increased fat oxidation and limited weight gain in obese mice (Heffernan et al., International Journal of Obesity, 2001, retrieved 2026-06-15). The early 12-week human trial produced a small 1.8 kg edge over placebo, and then the decisive 24-week trial showed "poor efficacy," ending the program (Wikipedia, "AOD9604", retrieved 2026-06-15). This is a common pattern in obesity research: many compounds shrink mice but not people, because rodent fat metabolism and dosing do not map cleanly onto human physiology. AOD-9604 is one of those compounds, which is exactly why the gulf between its current marketing and its actual record is so wide.

Our take: When a fat-loss peptide's sales pages quote mouse studies and a single small early result, but go quiet about the larger trial, that silence is the data point. AOD-9604's most honest one-line summary is: promising in mice, terminated in humans for lack of efficacy.

What is AOD-9604 actually evidenced to do?

Outside of mouse studies, AOD-9604 has no solid human evidence that it causes meaningful weight loss; the only repurposing direction with any animal support is joint cartilage, and that too is preclinical. It is best understood as a failed anti-obesity drug with a thin secondary research file, not a proven fat burner.

The honest way to read AOD-9604 is to separate what is claimed from what is evidenced. Marketing leans on the mouse lipolysis story and the early 1.8 kg human signal, while the decisive human data, the larger 24-week trial, showed poor efficacy (Wikipedia, "AOD9604", retrieved 2026-06-15). The most credible "second life" for the molecule is in osteoarthritis: an intra-articular injection of AOD-9604, with or without hyaluronic acid, enhanced cartilage regeneration in a rabbit knee-osteoarthritis model (Annals of Clinical & Laboratory Science, 2015, retrieved 2026-06-15). That is an interesting but very early, animal-only finding, and there is no completed human osteoarthritis efficacy trial to point to.

The table below is the heart of this article: the claimed effects next to what the evidence actually supports.

Because each of these is either a closed chapter (obesity) or a distinct future topic (the GH-fragment family, joint research), we keep them brief here. The headline: AOD-9604's reputation outran its evidence, and the human record is one of failure, not promise.

What doses of AOD-9604 do people report using?

There is no validated human dose for AOD-9604, and an important twist is that the failed trials used a 1 mg oral tablet, while the modern community convention is a much smaller subcutaneous injection, commonly cited around 250 to 500 mcg per day. These are reported figures, not an established or recommended dose, and there is no approved label to anchor them.

The most commonly cited community and clinic figure is roughly 250-500 mcg per day by subcutaneous injection, often taken fasted in the morning, with ~300 mcg frequently mentioned as a typical midpoint (Swolverine, "AOD-9604 Dosage Guide", 2025, retrieved 2026-06-15). It is worth sitting with the contradiction here: the doses people inject today are a different route and a much smaller amount than the 1 mg oral dose actually studied in the human obesity trials, and even that studied dose did not beat placebo. We label all of this as a community convention because no regulator has reviewed a dose and the human efficacy data are negative (Wikipedia, "AOD9604", retrieved 2026-06-15).

For orientation only, here is how people commonly describe the reported routes (not a recommendation):

The detailed titration math, reconstitution volumes, and stacking notes are a dedicated spoke. We cover only the high-level framing here and link out to our peptide dosing calculator and the general peptide injections guide.

Our take: A reported dose for a drug that failed its efficacy trials is doubly uncertain: it is not validated, and it is being used to chase an effect the human data did not find. We present these numbers only to describe what people do, never as a dose that "works."

What are the side effects of AOD-9604?

Because AOD-9604 has limited human safety data and no approved use, its true side-effect profile is not fully established; reported issues are mostly mild, such as injection-site reactions, while regulators have flagged manufacturing and immunogenicity concerns. In the trials it was generally well tolerated, but "generally tolerated in a failed drug" is not the same as "proven safe for ongoing use."

In the human obesity studies, AOD-9604 was reported as well tolerated, which is part of why it persisted as a research-chemical product even after the efficacy failure. But the safety conversation has shifted to product quality and manufacturing. In its December 2024 review, the FDA's advisory committee raised concerns about immunogenicity (the risk that injected peptide aggregates or impurities provoke an immune response) and a lack of publicly available impurity and sterility data for AOD-9604 as a compounding substance (U.S. FDA, "December 4, 2024 PCAC Meeting", 2024, retrieved 2026-06-15).

A hub-level overview of what is reported and what is flagged:

• Commonly reported (mild): injection-site redness, swelling, or irritation; occasional headache or fatigue (anecdotal).
• Quality-related risks: because the market is unregulated, contamination, mislabeled potency, aggregation, and impurities are real concerns independent of the peptide itself, and were specifically noted by the FDA advisory committee.
• Unknown: long-term safety in humans, because there is no approved, monitored long-term use and the development program ended in 2007.

This is the hub-level summary. A full side-effect and quality deep-dive is a dedicated spoke: AOD-9604 side effects and product-quality deep-dive.

How does AOD-9604 fit among growth-hormone peptides?

AOD-9604 sits in a family of growth-hormone-related compounds, but it is the odd one out: it is a fragment meant to act like part of the hormone, whereas the popular "GH peptides" people stack are secretagogues that make the body release its own growth hormone. This distinction matters because it is easy to lump AOD-9604 in with compounds that work very differently.

In rough terms, AOD-9604 is the C-terminal fragment of growth hormone itself, closely related to the compound sold as HGH Fragment 176-191. That is a different category from growth-hormone secretagogues such as the GHRH and ghrelin-mimetic peptides, which do not contain a piece of growth hormone but instead signal the pituitary to secrete more of it. So at a high level: AOD-9604 is a hormone fragment with a narrow (and unproven) fat-loss thesis, while the secretagogues are release-triggers with broader effects. The honest caveat that binds them together is that none in this casual "fat-loss / GH" cluster is an FDA-approved weight-loss drug.

That is the hub-level contrast, and it is deliberately brief to avoid overlapping the dedicated comparisons. AOD-9604 is itself the HGH Fragment 176-191, so for how it sits next to the secretagogue peptides see the growth-hormone peptide family.

Is AOD-9604 safe and legal?

AOD-9604 is not approved by any regulator, so there is no official safety determination, and it is not legal to sell or prescribe as an approved medicine or to include in dietary supplements; the products sold online are unapproved "research chemicals." That status matters more than any single study, especially for a compound that already failed its main trials.

On legality, AOD-9604 was never approved for therapeutic use by any government health authority, and as recently as December 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed it for the 503A bulk-substances list rather than treating it as an approved drug, raising safety and manufacturing concerns in the process (U.S. FDA, "December 4, 2024 PCAC Meeting", 2024, retrieved 2026-06-15). It is also banned in sport: AOD-9604 "is still banned in athletes and tested for in competition," and it was the central substance in the Essendon Football Club doping saga in Australian rules football, where its ambiguous status before anti-doping authorities clarified it caused a major controversy (Wikipedia, "AOD9604", retrieved 2026-06-15).

For the full legal picture and how to evaluate a vendor, see are peptides legal and how to vet peptide quality.

Our take: The most common misunderstanding is assuming that because AOD-9604 is sold openly online as a "fat-loss peptide," it must be a legitimate, working product. It is an unapproved drug that failed its weight-loss trials, is banned in sport, and is sold only "for research use only." Easy to buy is not the same as effective, legal, or safe.

How do people obtain AOD-9604?

Because AOD-9604 is unapproved, the main way people access it is by buying unapproved "research chemical" vials online, which is a legal and safety gray market with no quality guarantee. There is no legitimate "get a prescription for weight loss" route for an unapproved drug whose obesity program was terminated.

The research-peptide market is where most online searches end up: vendors sell lyophilized AOD-9604 "for research use only," and buyers reconstitute and inject it off-label, chasing a fat-loss effect the human trials did not deliver. That market carries real risks of mislabeled potency, impurities, and non-sterile product, with no regulatory oversight, the same quality gaps the FDA advisory committee flagged in 2024.

If you are researching that path despite the weak evidence, the responsible groundwork is the same as for any research peptide:

1. Confirm the legal status for your country and situation, including sport and workplace rules, since AOD-9604 is banned in competition. See are peptides legal.
2. Demand a certificate of analysis (COA) from independent third-party testing, and learn to read it for identity and purity. See how to vet peptide quality.
3. Calibrate your expectations to the evidence. Remember that the controlled human trials did not show meaningful weight loss; no protocol changes that.
4. Talk to a qualified clinician who can weigh your specific health situation, interactions, and contraindications.

We are describing what people do, not endorsing it. Using an unapproved drug that failed its trials means accepting unknown risks for an unproven benefit.

Frequently Asked Questions

The bottom line

AOD-9604 is the clearest example in the peptide world of a compound where the marketing kept going long after the science stopped. The original idea was genuinely clever: isolate the fat-burning tail of growth hormone, leave the rest behind, and you might have a clean weight-loss drug. In obese mice, that idea worked. That is the real reason it earned its "fat-burning fragment" reputation.

The other half of the story is the part the sales pages omit. When AOD-9604 was tested in obese adults, it managed only a small edge over placebo in a short trial and then failed the longer, decisive one, so its developer terminated the obesity program in 2007. On top of that, it is unapproved, banned in sport, flagged by the FDA over manufacturing quality, and sold only as an unregulated research chemical. The honest label is not "fat-burning peptide" but "failed anti-obesity candidate." If you take one thing from this hub, let it be the gap between "shrank mice" and "proven in people," and the value of a qualified clinician in navigating it. From here, the natural next reads are how to vet peptide quality, are peptides legal, and how peptides work.

Sources

• Wikipedia. "AOD9604." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/AOD9604
• Heffernan, M.A., Thorburn, A.W., Fam, B., et al. "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment." International Journal of Obesity, 2001 (PMID 11673763). Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/11673763/
• "Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model." Annals of Clinical & Laboratory Science, 2015 (PMID 26275694). Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/26275694/
• U.S. Food and Drug Administration. "Updated Meeting Information — December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee." 2024. Retrieved 2026-06-15. https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-meeting-time-and-public-participation-information-december-4-2024-meeting-pharmacy
• NCBI PubChem. "AOD-9604 (CID 71300630)." Retrieved 2026-06-15. https://pubchem.ncbi.nlm.nih.gov/compound/71300630
• Swolverine. "AOD-9604 Dosage Guide: Protocols, Benefits, Side Effects, Stacking and Cycle Lengths." 2025. Retrieved 2026-06-15. https://swolverine.com/blogs/blog/aod-9604-dosage-guide-protocols-benefits-side-effects-stacking-and-cycle-lengths
• Wikipedia. "Essendon Football Club supplements saga." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Essendon_Football_Club_supplements_saga